|
|
Post by Keybridge - Cult Member 003 on Aug 26, 2014 2:18:49 GMT
Surprised nobody brought this up.
Kite Pharma reported partial results from its phase 1-2a clinical trial for the company's T-Cell therapy (its only treatment in clinical trials) and has a market cap of approximately $850 million.
Kite Pharma announces patients with aggressive non-Hodgkin's lymphoma experience positive results after receiving anti-CD19 chimeric antigen receptor T Cells; 12 out of 13 evaluable patients had complete remissions or partial remissions.
Co announced the publication of clinical results in a cohort of patients demonstrating the potential to treat aggressive non-Hodgkin's lymphoma with an anti-CD19 chimeric antigen receptor (CAR) T cell therapy. Kite's most advanced product candidate, KTE-C19, is an anti-CD19 CAR T cell therapy that involves genetically modifying a patient's T cells to express a CAR that is designed to target CD19, a protein expressed on the cell surface of B cell lymphomas and leukemias.
The findings from an ongoing Phase 1-2a clinical trial funded by Kite and conducted by the Surgery Branch of the National Cancer Institute (NCI) demonstrated that in 12 out of 13 evaluable patients with advanced B-cell malignancies, administration of anti-CD19 CAR T cells resulted in complete remission in eight patients and partial remission in four patients, representing an overall objective response rate of 92%. Of seven evaluable patients with chemotherapy-refractory DLBCL, four achieved complete remission, three of which are ongoing with durations ranging from 9 to 22 months.
Based on this substantial progress, Kite plans to file an IND in the fourth quarter of this year to initiate a Phase 1-2 single-arm multicenter clinical trial of KTE-C19 in patients with DLBCL who have failed two or more lines of therapy. We are excited to advance this promising therapy and anticipate commencing patient enrollment in our DLBCL clinical trial in the first half of 2015."
|
|
|
|
Post by JHam on Aug 26, 2014 3:24:17 GMT
Surprised nobody brought this up. Kite Pharma reported partial results from its phase 1-2a clinical trial for the company's T-Cell therapy (it's only treatment in clinical trials) and has a market cap of approximately $850 million.
Kite Pharma announces patients with aggressive non-Hodgkin's lymphoma experience positive results after receiving anti-CD19 chimeric antigen receptor T Cells; 12 out of 13 evaluable patients had complete remissions or partial remissions. Co announced the publication of clinical results in a cohort of patients demonstrating the potential to treat aggressive non-Hodgkin's lymphoma with an anti-CD19 chimeric antigen receptor (CAR) T cell therapy. Kite's most advanced product candidate, KTE-C19, is an anti-CD19 CAR T cell therapy that involves genetically modifying a patient's T cells to express a CAR that is designed to target CD19, a protein expressed on the cell surface of B cell lymphomas and leukemias. The findings from an ongoing Phase 1-2a clinical trial funded by Kite and conducted by the Surgery Branch of the National Cancer Institute (NCI) demonstrated that in 12 out of 13 evaluable patients with advanced B-cell malignancies, administration of anti-CD19 CAR T cells resulted in complete remission in eight patients and partial remission in four patients, representing an overall objective response rate of 92%. Of seven evaluable patients with chemotherapy-refractory DLBCL, four achieved complete remission, three of which are ongoing with durations ranging from 9 to 22 months. Based on this substantial progress, Kite plans to file an IND in the fourth quarter of this year to initiate a Phase 1-2 single-arm multicenter clinical trial of KTE-C19 in patients with DLBCL who have failed two or more lines of therapy. We are excited to advance this promising therapy and anticipate commencing patient enrollment in our DLBCL clinical trial in the first half of 2015." Good news for Kite and the patients, but why are you surprised no one brought it up? |
|
|
|
Post by Keybridge - Cult Member 003 on Aug 26, 2014 12:10:23 GMT
For a small biotech still in phase I with a market cap nearly 4X ACT's (with a press release that was widely disseminated), seems that it would have been noticed and commented on…we've had similar discussions before.
As a side note, it has personal relevance to me since many years ago I lost a good friend to a rare form of non-Hodgkin's who was in fact enrolled in some type of clinical trial at NCI…good to see progress.
Note: Kite closed today with a market cap of $1 billion...not bad for a company that has treated only 13 patients.
|
|
|
|
Post by tatshensini on Jul 27, 2016 23:18:55 GMT
Great News today for KITE Pharma, and entering into an exclusive licensing with the NIH....this company is tracking like I had expected ACTC to do...glad I bought when I did. www.businesswire.com/news/home/20160727006484/en/Kite-Pharma-Announces-Exclusive-License-National-InstitutesHuman Anti-CD19 Chimeric Antigen Receptor (CAR) Product Candidate to Treat B-Cell Malignancies July 27, 2016 04:05 PM Eastern Daylight Time SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T-cell therapy (eACT™) products for the treatment of cancer, today announced that the Company has entered into an exclusive, worldwide license with the National Institutes of Health (NIH) for intellectual property related to a fully human anti-CD19 chimeric antigen receptor-based product candidate directed against B-cell malignancies. The National Cancer Institute (NCI), with Dr. James N. Kochenderfer, M.D., an investigator in the Experimental Transplantation and Immunology Branch of the NCI, is currently conducting a Phase 1 clinical trial of the product candidate in patients with B-cell malignancies under an existing Cooperative Research and Development Agreement (CRADA) between Kite and the NCI. "The expansion of our CAR-T pipeline to include a fully human anti-CD19 chimeric antigen receptor supports our effort to maximize the potential benefit of CAR-T therapies for patients with advanced B-cell malignancies. As the field of T-cell therapy continues its rapid advancement, we remain committed to collaborating with the world’s most distinguished institutions and accessing the most significant enabling technologies to pioneer the next generation of T-cell therapies," said Arie Belldegrun, M.D., FACS, Chairman, President, and Chief Executive Officer. And this yesterday: www.smarteranalyst.com/2016/07/25/company-update-nasdaqkite-kite-pharma-inc-licenses-enabling-technology-development-off-shelf-allogeneic-t-cell-therapies/ |
|
